Skip to main content
italianoIT
European Commission logo print header

Rheuma Tolerance for Cure

Obiettivo

In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progression by inhibiting maturation/expansion of pathogenic autoimmune responses through immune tolerising treatments of subjects not only in early
stages of joint inflammation (undifferentiated arthritis and early RA) but also in even earlier defined stages i.e. before onset of joint inflammation, when patients have arthralgia and/or bone loss, or sub-clinical stages of joint inflammation.

Today, no drugs are approved for these early phases of RA development, where symptoms such as pain and fatigue cause major loss of life quality and where successful interference would prevent onset of disease. Thus, an important part of our work will be to achieve a better understanding of this as yet unexplored phase of disease. In the proposed project we will develop and validate new methods to identify individuals at high risk for RA, tools to monitor disease progress and expand and further develop cohorts suitable for these purposes.
Furthermore we will validate and standardise methods to monitor immune tolerance to be used in clinical trials for tolerising therapies for RA.
The aim is thus to interfere with the specific immune reactions that contribute to RA symptoms in such a way that a specific and long-lasting therapeutic effect (ultimately a cure) is accomplished for a major proportion of RA patients and prevention of diseases is accomplished in individuals at high risk for RA.

Investigator-initiated as well as company-sponsored clinical trials in well stratified patient groups will be performed in collaboration with SMEs and/or contributing pharma companies and their immune effects studied using the same panel of biomarkers allowing for standardisation across protocols. Our ambition is also to disseminate our experiences from RA to other rheumatic and other immune-mediated diseases.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

H2020-JTI-IMI2-2016-09-two-stage

Vedi altri progetti per questo bando

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

KAROLINSKA INSTITUTET
Contribution nette de l'UE
€ 1 293 375,61
Indirizzo
Nobels vag 5
17177 Stockholm
Svezia

Mostra sulla mappa
Regione
Östra Sverige Stockholm Stockholms län
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Altri finanziamenti
€ 384 714,04

Partecipanti (19)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 13 Novembre 2023

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/777357/it

European Union, 2023